Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cartil-S and Chondroseal are autologous cell therapies developed by Octomera (an Orgenesis company) for the treatment of osteoarthritis and cartilage defects. Cartil-S is an autologous activated adipose-derived stem cell therapy. Chondroseal is a Gel-Type Autologous Stem Cell Implantation (GTASCI) that utilizes cultured autologous cells, such as adipose-derived stem cells or chondrocytes, combined with a natural gel scaffold for three-dimensional arthroscopic transplantation. These therapies are designed to restore articular cartilage by promoting local regeneration within the joint. They are currently listed as being in clinical use, indicating availability for patient treatment in specific markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cartil-S + Chondroseal.